The global non-invasive cancer diagnostics market size was valued at USD 79.96 billion in 2025 and is projected to grow from USD 85.34 billion in 2026 to USD 145.59 billion by 2034, registering a CAGR of 6.91% during the forecast period (2026–2034). North America dominated the non-invasive cancer diagnostics market with a market share of 41.30% in 2025.
Non-invasive cancer diagnostics are advanced medical technologies used to detect and monitor cancer through blood, imaging, and molecular analysis without surgical intervention. These methods enable early disease detection, personalized treatment planning, and improved patient outcomes while reducing discomfort and procedural risks. They are increasingly applied in oncology, screening, and monitoring programs worldwide.
The non-invasive cancer diagnostics market demand is increasing due to rising cancer incidence, growing preference for early diagnosis, and advancements in diagnostic technologies. Healthcare providers are adopting these solutions to enhance accuracy and accessibility of cancer detection. Increasing research, expanding healthcare infrastructure, and technological innovations are also contributing to non-invasive cancer diagnostics market growth.
Download a Free Sample To learn more about this report,
The non-invasive cancer diagnostics market has limited exposure to supply chain disruptions due to its reliance on specialized diagnostic equipment, molecular testing components, reagents, and advanced imaging technologies sourced through global supply networks. Supply chain challenges, including delays in raw material availability, semiconductor shortages, and logistics constraints, have influenced the production and distribution of diagnostic devices and testing solutions, shaping market dynamics and increasing the focus on localized manufacturing and resilient supply strategies. The market is expected to follow an S-shaped recovery pattern, with gradual stabilization through improved supply chain diversification, technological advancements, and increased investment in healthcare infrastructure supporting steady long-term growth.
Expansion of Multi-cancer Early Detection Testing Using Genomic Biomarkers
The adoption of multi-cancer early detection tests is becoming a key trend in the non-invasive cancer diagnostics market as healthcare systems move toward screening approaches that identify multiple cancer types from a single blood sample. These tests use genomic signatures, methylation patterns, and circulating biomarkers to detect cancers at earlier stages, improving screening efficiency and enabling proactive treatment pathways.
Growing Use of Digital Biomarkers and Wearable-based Cancer Monitoring Technologies
The integration of digital biomarkers is emerging as a significant trend in the non-invasive cancer diagnostics market as remote monitoring technologies enable continuous tracking of patient health indicators beyond traditional clinical assessments. These solutions use wearable sensors, mobile health platforms, and patient-generated data to support treatment monitoring, detect disease progression, and improve personalized cancer care.
The non-invasive cancer diagnostics market forecasts continued investment activity driven by the rising adoption of liquid biopsy, multi-cancer early detection technologies, and precision oncology. In 2026, GRAIL announced the successful completion of a USD 110 million equity financing led by Samsung affiliates. The funding will support the international expansion of the Galleri multi-cancer early detection blood test, accelerate regulatory approval activities across key markets, strengthen reimbursement initiatives, and expand commercialization efforts.
Increasing Clinical Adoption of Minimal Residual Disease Testing and Expansion of Biomarker-based Drug Development Drives Market
The growing use of minimal residual disease testing is driving demand for non-invasive cancer diagnostics by enabling clinicians to detect microscopic traces of cancer after treatment through blood samples. Healthcare providers are increasingly using MRD assays to identify recurrence earlier than conventional imaging, supporting timely therapeutic interventions and long-term disease monitoring. This is increasing demand for highly sensitive circulating tumor DNA technologies across oncology centers.
The increasing number of biomarker-driven oncology clinical trials is driving demand for non-invasive cancer diagnostics by enabling rapid patient stratification and continuous monitoring without repeated tissue biopsies. Pharmaceutical companies are integrating liquid biopsy and circulating biomarker analysis into clinical studies to improve patient enrollment, evaluate treatment response, and accelerate drug development. This is boosting demand for advanced genomic sequencing platforms and blood-based companion diagnostic technologies while supporting the development of targeted cancer therapies.
Limited Clinical Validation Across Diverse Cancer Types and Low Tumor DNA Shedding in Early-stage Cancers Restrain Market Expansion
Non-invasive cancer diagnostics rely on extensive clinical validation to demonstrate accuracy across different cancer types, stages, and patient populations. Many emerging biomarker assays still require large-scale prospective studies before they can be routinely adopted in clinical practice. This slows regulatory acceptance, physician confidence, and integration into standard cancer care pathways. Thus, limited clinical validation remains a significant restraint for the non-invasive cancer diagnostics market.
Many non-invasive cancer diagnostic tests depend on detecting circulating tumor DNA or other tumor-derived biomarkers in blood. Early-stage tumors often release very low concentrations of these biomarkers, making detection technically challenging and increasing the risk of false-negative results. This limits the effectiveness of blood-based diagnostics for population-wide early cancer screening and reduces physician confidence in certain clinical settings.
Development of Exosome-based Cancer Diagnostics and Integration of Non-invasive Diagnostics into Decentralized Testing Networks Offer Growth Opportunities
The growing focus on exosome-based diagnostics presents a promising opportunity for biotechnology companies, molecular diagnostics developers, and research organizations. Unlike conventional liquid biopsy, exosomes carry intact RNA, DNA, and proteins that provide comprehensive molecular information even in early-stage cancers, supporting improved diagnostic sensitivity. As exosome isolation technologies become standardized and gain regulatory acceptance, they are expected to create new product categories within non-invasive cancer diagnostics.
The expansion of decentralized diagnostic networks creates a strong growth opportunity for manufacturers of non-invasive cancer diagnostic platforms, molecular testing companies, and independent laboratory providers. Healthcare systems are increasingly moving cancer testing closer to patients through regional laboratories and community diagnostic centers, reducing dependence on tertiary hospitals. As automated sample processing and cloud-enabled data analysis improve accessibility, demand for portable and high-throughput non-invasive diagnostic solutions is expected to increase, offering growth opportunities.
High Initial Investments and Diverse Datasets Challenges Market Growth
The growing adoption of non-invasive cancer diagnostics is increasing the need for laboratories capable of processing high volumes of next-generation sequencing and liquid biopsy samples while maintaining fast turnaround times and analytical accuracy. Expanding sequencing infrastructure, automation, and specialized molecular pathology expertise requires substantial investment, limiting the pace of market expansion in many regions.
Non-invasive cancer diagnostics are increasingly generating genomic, epigenomic, proteomic, and transcriptomic data from a single patient sample. However, integrating these diverse datasets into clinically actionable reports remains technically complex and requires advanced bioinformatics infrastructure and specialized expertise. This limits routine adoption in many healthcare institutions and slows the clinical scalability of next-generation non-invasive diagnostic platforms.
The instruments segment accounted for a share of 59.46% in 2025, as advanced sequencing platforms and high-throughput molecular analyzers form the core infrastructure for non-invasive cancer diagnostics. Their long operational life, integration with automated laboratory workflows, and continuous software upgrades strengthened procurement across reference laboratories.
The kits & reagents segment is expected to grow at a CAGR of around 8.65% during the forecast period due to recurring consumption in every diagnostic procedure and increasing availability of cancer specific biomarker panels. Growing demand for standardized assay chemistry and multiplex detection reagents further accelerates replacement cycles and purchasing frequency.
Request Customizationto receive a tailored report.
The imaging segment accounted for a share of 40.01% in 2025, owing to its established role in detecting anatomical abnormalities before molecular confirmation and its widespread availability across healthcare facilities. Continuous improvements in functional imaging resolution and AI-assisted lesion characterization further strengthened its clinical utilization for cancer evaluation.
The liquid biopsy segment is expected to grow at a CAGR of 8.43% during the forecast period, driven by expanding applications in longitudinal treatment monitoring and the ability to capture tumor heterogeneity from circulating biomarkers. Increasing use of circulating tumor DNA analysis for therapy selection further supports rapid technology adoption.
The liver cancer segment accounted for a share of 16.87% in 2025 due to increasing surveillance of patients with chronic hepatitis and cirrhosis using non-invasive diagnostic approaches. Strong demand for biomarker-based detection alongside routine imaging further supported widespread clinical adoption within hepatology care pathways.
The lung cancer segment is expected to grow at a CAGR of 9.01% during the forecast period, driven by rising adoption of blood-based genomic profiling for identifying actionable mutations and monitoring therapeutic response. Expanding targeted therapy eligibility has increased demand for rapid, minimally invasive molecular testing solutions.
The diagnostic laboratories segment accounted for a share of 49.82% in 2025, due to centralized high-throughput testing capabilities and access to sophisticated molecular sequencing infrastructure unavailable in most clinical settings. Their ability to process large specimen volumes with standardized quality assurance supported dominant market participation.
The hospitals segment is projected to grow at a CAGR of 9.10% during the forecast period, as oncology departments increasingly integrate non-invasive diagnostics into multidisciplinary cancer management and treatment planning. Rising investments in in-house molecular pathology laboratories and precision oncology programs continue to accelerate hospital-based testing adoption.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Precision Oncology Adoption and Advanced Molecular Diagnostic Infrastructure
The North America non-invasive cancer diagnostics market accounted for the largest regional share of 41.30% in 2025, driven by widespread adoption of precision oncology, strong availability of advanced molecular diagnostic laboratories, and increasing utilization of liquid biopsy and multi-cancer early detection technologies. The region also benefits from favorable reimbursement for select molecular tests, extensive cancer research activities, and rapid commercialization of innovative diagnostic platforms.
The US non-invasive cancer diagnostics market was valued at USD 28.73 billion in 2025, driven by increasing integration of liquid biopsy into routine oncology care and growing adoption of precision medicine across major cancer centers. Healthcare providers are investing in blood-based molecular diagnostics to support early detection, therapy selection, and disease monitoring while reducing dependence on invasive tissue biopsies. According to the American Cancer Society, the US is expected to record over 2 million new cancer cases in 2025, supporting sustained demand for early cancer detection technologies.
The non-invasive cancer diagnostics market in Canada was valued at USD 4.29 billion in 2025, supported by expanding provincial cancer screening initiatives and increasing investment in precision medicine programs. Healthcare systems are adopting minimally invasive molecular diagnostics to improve early cancer detection and optimize patient management while reducing diagnostic burden.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Expansion of National Genomic Medicine Programs and Rising Adoption of Population-based Cancer Screening
The Asia Pacific non-invasive cancer diagnostics market is expected to grow at a CAGR of 9.49% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding national genomic medicine initiatives, increasing investments in molecular diagnostics, and growing implementation of population-based cancer screening programs. According to the International Agency for Research on Cancer (IARC), Asia accounted for nearly 49% of global new cancer cases in 2022, creating sustained demand for early, non-invasive diagnostic technologies.
The China non-invasive cancer diagnostics market was valued at USD 4.67 billion in 2025, supported by rapid expansion of National Cancer Regional Medical Centers, increasing deployment of next-generation sequencing laboratories in Class III hospitals, and government-backed precision medicine initiatives under the Healthy China 2030 strategy. The growing adoption of domestically developed liquid biopsy assays and expanding reimbursement pilots for molecular diagnostics in selected provinces also drive growth.
The India non-invasive cancer diagnostics market was valued at USD 2.34 billion in 2025, fueled by growth of NABL-accredited molecular diagnostic laboratories, increasing availability of next-generation sequencing services through private oncology chains, and growing integration of precision oncology in tertiary cancer centers. The National Programme for Prevention and Control of Non-Communicable Diseases improves access to advanced cancer diagnostics across Tier I and Tier II cities continue to strengthen market growth.
The Japan non-invasive cancer diagnostics market was valued at USD 2.78 billion in 2025, supported by Japan’s genomic medicine network and increasing clinical adoption of comprehensive genomic profiling for oncology care. Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT) continues to expand the utilization of genomic data, strengthening demand for blood-based molecular diagnostics and precision cancer testing across designated cancer hospitals.
The non-invasive cancer diagnostics market competitive landscape is moderately consolidated, with competition led by established molecular diagnostics, genomics, and precision oncology companies alongside innovative biotechnology firms. Market participants compete through advancements in liquid biopsy technologies, biomarker discovery, next-generation sequencing, artificial intelligence integration, and strategic collaborations with healthcare providers and pharmaceutical companies.
June 2026: Guardant Health announced FDA approval of Guardant360 CDx as the companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib).
May 2026: Guardant Health received US FDA approval for the new Guardant360 Liquid CDx, the largest FDA approved liquid biopsy panel integrating genomic and epigenomic profiling.
March 2026: Guardant Health partnered with Manulife to launch the Shield Multi-Cancer Detection (MCD) test across Hong Kong, Singapore, and the Philippines.
September 2025: Exact Sciences Corporation announced the commercial launch of the Cancerguard multi-cancer early detection blood test in the US.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
Cell-free DNA Testing Market Size, Share, Growth, 2034
RNA Therapeutics Market Size, Share, Growth, Forecast, 2034
Mitochondrial DNA (mtDNA) Market Size, Share, Growth, Analysis, 2034
Biopharmaceutical Fermentation Systems Market Size, Share, Growth, 2034
Red Biotechnology Market Size, Share, Growth, Forecast, 2034
Cell Freezing Media Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com